{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-025232","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.175260+00:00","generated_at":"2026-05-26T06:23:50.706476+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"PepGen reports robust splicing correction in DM1 trial; 29.1% mean correction at 10 mg/kg single dose","bullets":["Mean splicing correction of 12.3% (5 mg/kg, n=6) and 29.1% (10 mg/kg, n=4) at 28 days post single dose.","Favorable emerging safety profile; one treatment-related SAE of abdominal pain potentially confounded.","Cash $120.2M as of Dec 31, 2024, expected to fund operations into 2026.","Net loss $90.0M for FY2024 ($2.85/share) vs $78.6M ($3.30/share) in FY2023.","15 mg/kg cohort results expected H2 2025; CONNECT1-EDO51 10 mg/kg fully enrolled with results Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-025232","json":"https://secwatch.observer/filing/0000950170-25-025232.json","markdown":"https://secwatch.observer/filing/0000950170-25-025232.md","text":"https://secwatch.observer/filing/0000950170-25-025232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017025025232/0000950170-25-025232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017025025232/pepg-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:23:50.706476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}